Page 39 - Demo

10.1093/schbul/sbu006.5. Patel, K.R., et al., Schizophrenia: overview and treatmentoptions. P T, 2014. 39(9):p. 638-45.6. Remington, G., et al., Guidelines for thePharmacotherapy of Schizophrenia in Adults. Can JPsychiatry, 2017. 62(9): p. 604-616, DOI:10.1177/0706743717720448.7. Brisch, R., et al., The role of dopamine in schizophreniafrom a neurobiological and evolutionary perspective:old fashioned, but still in vogue. Front Psychiatry,2014. 5: p. 47, DOI: 10.3389/fpsyt.2014.00047.8. Shen, L.H., M.H. Liao, and Y.C. Tseng, Recent advances inimaging of dopaminergic neurons for evaluation ofneuropsychiatric disorders. J Biomed Biotechnol, 2012.2012: p. 259349, DOI: 10.1155/2012/259349.9. Howes, O.D. and R.M. Murray, Schizophrenia: anintegrated sociodevelopmental- cognitive model.Lancet, 2014. 383(9929): p. 1677-1687, DOI:10.1016/S0140- 6736(13)62036-X.10. O%u2019Donnell, P. and A.A. Grace, Dysfunctions in multipleinterrelated systems as the neurobiological bases ofschizophrenic symptom clusters. Schizophr Bull, 1998.24(2): p. 267-83, DOI:10.1093/oxfordjournals.schbul.a033325.11. Simpson, E.H., et al., Selective overexpression ofdopamine D3 receptors in the striatum disruptsmotivation but not cognition. Biol Psychiatry, 2014.76(10): p. 823- 31, DOI:10.1016/j.biopsych.2013.11.023.12. Lally, J. and J.H. MacCabe, Antipsychotic medication inschizophrenia: a review. Br Med Bull, 2015. 114(1): p.169-79, DOI: 10.1093/bmb/ldv017.13. Cohen, D., et al., Hyperglycemia and diabetes in patientswith schizophrenia or schizoaffective disorders.Diabetes Care, 2006. 29(4): p. 786-91.14. Casey, D.E., Dyslipidemia and atypical antipsychoticdrugs. J Clin Psychiatry, 2004. 65 Suppl 18: p. 27-35.15. Kurzthaler, I. and W.W. Fleischhacker, The clinicalimplications of weight gain in schizophrenia. J ClinPsychiatry, 2001. 62 Suppl 7: p. 32-7.16. Manu, P., et al., Weight gain and obesity in schizophrenia:epidemiology, pathobiology, and management. ActaPsychiatr Scand, 2015. 132(2): p. 97-108, DOI:10.1111/acps.12445.17. Luo, L. and M. Liu, Adipose tissue in control ofmetabolism. J Endocrinol, 2016. 231(3): p. R77-R99,DOI: 10.1530/JOE-16-0211.18. Tan, C.Y. and A. Vidal-Puig, Adipose tissue expandability:the metabolic problems of obesity may arise from theinability to become more obese. Biochem Soc Trans,2008. 36(Pt 5): p. 935-40, DOI: 10.1042/BST0360935.19. Kajimura, S., Adipose tissue in 2016: Advances in theunderstanding of adipose tissue biology. Nat RevEndocrinol, 2017. 13(2): p. 69-70, DOI:10.1038/nrendo.2016.211.20. Seale, P., et al., PRDM16 controls a brown fat/skeletalmuscle switch. Nature, 2008.454(7207): p. 961-7, DOI:10.1038/nature07182.21. Lepper, C. and C.M. Fan, Inducible lineage tracing ofPax7-descendant cells reveals embryonic origin ofadult satellite cells. Genesis, 2010. 48(7): p. 424-36,DOI: 10.1002/dvg.20630.22. Aherne, W. and D. Hull, Brown adipose tissue and heatproduction in the newborn infant. J Pathol Bacteriol,tratamiento con FASG podr%u00edan deberse a unaintercomunicaci%u00f3n defectuosa entre la grasa y elh%u00edgado/m%u00fasculo esquel%u00e9tico, que son tejidos clave parala lipog%u00e9nesis de novo o la captaci%u00f3n de glucosa,respectivamente.En conclusi%u00f3n, a pesar de los grandes avanceslogrados en nuestra comprensi%u00f3n de las alteracionesmetab%u00f3licas de los tratamientos con los FASG, serequieren m%u00e1s investigaciones para abordarcompletamente el impacto de estos f%u00e1rmacos en losdiferentes dep%u00f3sitos de tejido adiposo del organismo yel interactoma entre ellos ya sea por mol%u00e9culasinflamatorias, adipoquinas y/u otros compuestosactivadores o inhibidores, as%u00ed como las conexiones entreel SNC y el tejido adiposo.LISTA DE ABREVIATURASACS, c%u00e9lulas madre derivadas del tejido adiposo (delingl%u00e9s, adipose-derived stem cells); AMPK, prote%u00ednaquinasa activada por AMP (del ingl%u00e9s, adenosinemonophosphate-activated protein kinase); ATGL,triglic%u00e9rido lipasa del tejido adiposo (del ingl%u00e9s, adiposetriglyceride lipase); Insig, gen inducido por la insulina(del ingl%u00e9s, Insulin-induced gene); FAPG, f%u00e1rmacosantipsic%u00f3ticos de primera generaci%u00f3n; FAS, %u00e1cido grasosintasa (del ingl%u00e9s, Fatty acid synthase); FASG,f%u00e1rmacos antipsic%u00f3ticos de segunda generaci%u00f3n; HSL,lipasa sensible a hormonas (del ingl%u00e9s, hormonesensitive lipase); IBMX, 3-isobutil-1-metilxantina; MCP1, prote%u00edna quimioatrayente de monocitos 1 (del ingl%u00e9s,Monocyte chemoattractant protein- 1); MSC, c%u00e9lulasmadre mesenquimales; PLIN, perilipina; PGC-1a,coactivador gamma 1 alfa del receptor activado porproliferador de peroxisomas (del ingl%u00e9s, peroxisomeproliferator-activated receptor-%u03b3 coactivator-1a);PPAR-g, receptor activado por el proliferador deperoxisomas gamma (del ingl%u00e9s, peroxisomeproliferator-activated receptor gamma); SCAP, prote%u00ednaactivadora de escisi%u00f3n de SREBP (del ingl%u00e9s, SREBPcleavage- activating protein); SNC, sistema nerviosocentral; SREBP, prote%u00ednas reguladoras de elementos deuni%u00f3n a esteroles (del ingl%u00e9s, Sterol regulatoryelement-binding proteins); T2D, diabetes mellitus tipo2; TAB, tejido adiposo blanco; TAM, tejido adiposomarr%u00f3n; TG, triglic%u00e9ridos; UCP-1, Prote%u00ednadesacomplante 1 (del ingl%u00e9s, Uncoupling protein 1).6. REFERENCIAS1. Rosen, W.G., et al., Positive and negative symptoms inschizophrenia. Psychiatry Res, 1984. 13(4): p. 277-84.2. Carra, G., et al., Positive and negative symptoms inschizophrenia: A longitudinal analysis using latentvariable structural equation modelling. Schizophr Res,2019. 204: p. 58-64, DOI:10.1016/j.schres.2018.08.018.3. Fleischhacker, W.W., et al., Schizophrenia%u2014time tocommit to policy change.4. Schizophr Bull, 2014. 40 Suppl 3: p. S165-94, DOI:38ANALESRANFwww.analesranf.comSecond-generation antipsychotic drugs and their impact onadipose tissuePatricia Rada, V%u00edtor Ferreira y %u00c1ngela M. ValverdeAn. R. Acad. Farm.Vol. 90. n%u00ba 1 (2024) %u00b7 pp. 21-44